This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.
If you have previously purchased this report then please use the download links on the right to download the files.
| 1. | EXECUTIVE SUMMARY |
| 1.1. | The Scope of Synthetic Biology is Vast |
| 1.2. | Important Societal, Economic and Environmental Factors |
| 1.3. | Drivers and Barriers for Adoption of Synthetic Biology |
| 1.4. | The Global Differences in Regulation for Genetic Engineering |
| 1.5. | 2018 is Set to Be Another Record-Breaking Year |
| 1.6. | Key Applications |
| 1.7. | Key Players in Organism Engineering |
| 1.8. | The Outlook for Synthetic Biology in Organism Engineering |
| 1.9. | Key Players in Food and Agriculture |
| 1.10. | The Outlook for Synthetic Biology in Food and Agriculture |
| 1.11. | Key Players in Materials and Consumer Products |
| 1.12. | The Outlook for Synthetic Biology in Engineering Materials |
| 1.13. | Key Players in Specialty Chemicals |
| 1.14. | The Outlook for Synthetic Biology in Specialty Chemicals |
| 1.15. | The Range of Biobased Monomers |
| 1.16. | A Rapidly Growing but Uncertain Technology |
| 1.17. | Suppliers of PHAs |
| 1.18. | Applications and Opportunities for PHAs |
| 1.19. | Suppliers of Lactide and Poly(lactide) |
| 1.20. | Current and Future Applications of Poly(lactide) |
| 1.21. | Biobased Polyester Suppliers |
| 1.22. | Key Players in Human Therapeutics |
| 1.23. | The Outlook for Synthetic Biology in Human Therapeutics |
| 1.24. | Synthetic Biology Funding Continues to Increase |
| 1.25. | Investment Forecast 2018 - 2023 |
| 2. | INTRODUCTION |
| 2.1. | The Design and Engineering of Biological Systems |
| 2.2. | Manipulating the Central Dogma |
| 2.3. | The Scope of Synthetic Biology is Vast |
| 2.4. | Important Societal, Economic and Environmental Factors |
| 2.5. | The Process of Synthetic Biology: Design, Build and Test |
| 2.6. | Cell Factories for Biomanufacturing: A Range of Organisms |
| 2.7. | Technological Advances Resulting from Synthetic Biology |
| 2.8. | Why Now for Synthetic Biology? |
| 2.9. | From Pharmaceuticals to Consumer Products |
| 2.10. | Disruption of Existing Supply Chains |
| 2.11. | Drivers and Barriers for Adoption of Synthetic Biology |
| 3. | TOOLS AND TECHNIQUES |
| 3.1.1. | Outline |
| 3.1.2. | The Techniques and Tools of Synthetic Biology |
| 3.1.3. | DNA Synthesis |
| 3.1.4. | Applications for DNA Synthesis |
| 3.1.5. | Twist Bioscience |
| 3.1.6. | Gene Editing |
| 3.2. | CRISPR-Cas9 |
| 3.2.1. | What Exactly is CRISPR-Cas9? |
| 3.2.2. | CRISPR-Cas9: A Bacterial Immune System |
| 3.2.3. | Why is CRISPR-Cas9 so Important for Synthetic Biology? |
| 3.2.4. | Who Owns CRISPR-Cas9 and Why is it so Problematic? |
| 3.2.5. | An Update on the Ongoing Patent Battle |
| 3.2.6. | Commercializing CRISPR-Cas9 |
| 3.2.7. | Licensing Agreements with Commercial Enterprises |
| 3.2.8. | Companies are Finding Ways of Avoiding Royalties |
| 3.2.9. | Products Engineered Using CRISPR-Cas9 |
| 3.2.10. | Clinical Trials Testing CRISPR-Cas9 in Humans Have Started |
| 3.2.11. | Alternatives to CRISPR-Cas9 Exist |
| 3.2.12. | The Outlook for CRISPR-Cas9 |
| 3.3. | Protein Engineering |
| 3.3.1. | Protein/Enzyme Engineering |
| 3.3.2. | Computer-Aided Design |
| 3.3.3. | Commercial Examples of Engineered Proteins |
| 3.3.4. | Strain Construction and Optimization |
| 3.3.5. | Framework for Developing Industrial Microbial Strains |
| 3.3.6. | The Problem with Scale |
| 3.3.7. | Commercial Examples of Strain Development |
| 3.3.8. | Cell-Free Systems |
| 3.3.9. | Cell-Free versus Cell-Based Systems |
| 3.3.10. | Robotics: Enabling Hands-Free and High-Throughput Science |
| 3.3.11. | Robotic Cloud Laboratories |
| 3.3.12. | Automating Organism Design and Closing the Loop |
| 3.3.13. | Artificial Intelligence and Machine Learning |
| 4. | APPLICATIONS |
| 4.1. | Organism Engineering |
| 4.1.1. | Key Players in Organism Engineering |
| 4.1.2. | Ginkgo Bioworks |
| 4.1.3. | Ginkgo's Automated Approach to Strain Engineering |
| 4.1.4. | Zymergen |
| 4.1.5. | DEINOVE |
| 4.1.6. | Arzeda |
| 4.1.7. | Arzeda: Computational Design, HTS and Data Science |
| 4.1.8. | The Outlook for Synthetic Biology in Organism Engineering |
| 4.2. | Food and Agriculture |
| 4.2.1. | Key Players in Food and Agriculture |
| 4.2.2. | Perfect Day |
| 4.2.3. | Impossible Foods |
| 4.2.4. | Clara Foods |
| 4.2.5. | Geltor |
| 4.2.6. | MiraculeX |
| 4.2.7. | The Outlook for Synthetic Biology in Food and Agriculture |
| 4.3. | Materials and Consumer Products |
| 4.3.1. | Key Players in Materials and Consumer Products |
| 4.3.2. | Manufacturing Spider Silk |
| 4.3.3. | Applications for Spider Silk |
| 4.3.4. | Spider Silk Without Spiders |
| 4.3.5. | Bolt Threads |
| 4.3.6. | Spiber |
| 4.3.7. | Kraig Biocraft Laboratories |
| 4.3.8. | Modern Meadow |
| 4.3.9. | Biofabrication of Leather |
| 4.3.10. | A Competitor for Modern Meadow? |
| 4.4. | Specialty Chemicals |
| 4.4.1. | Key Players in Specialty Chemicals |
| 4.4.2. | Metabolic Explorer |
| 4.4.3. | Arzeda |
| 4.4.4. | Green Biologics |
| 4.4.5. | GreenLight Biosciences |
| 4.4.6. | Novozymes |
| 4.4.7. | The Outlook for Synthetic Biology in Specialty Chemicals |
| 4.5. | Biobased Polymers |
| 4.5.1. | The Range of Biobased Monomers |
| 4.5.2. | A Rapidly Growing but Uncertain Technology |
| 4.5.3. | Polyesters |
| 4.5.4. | Introduction to Poly(hydroxyalkanoates) |
| 4.5.5. | Suppliers of PHAs |
| 4.5.6. | PHAs: Microstructures and Properties |
| 4.5.7. | Biosynthetic Pathways to PHAs |
| 4.5.8. | Applications and Opportunities for PHAs |
| 4.5.9. | Polyesters |
| 4.5.10. | Introduction to Poly(lactide) |
| 4.5.11. | Optimal Lactic Acid Bacteria Strains for Fermentation |
| 4.5.12. | Engineering Yeast Strains for Lactic Acid Fermentation |
| 4.5.13. | Fermentation, Recovery and Purification |
| 4.5.14. | Suppliers of Lactide and Poly(lactide) |
| 4.5.15. | Current and Future Applications of Poly(lactide) |
| 4.5.16. | Other Biobased Polymers |
| 4.5.17. | The Range of Available Biobased Polyesters in 2018 |
| 4.5.18. | Biobased Polyester Suppliers |
| 4.6. | Human Therapeutics |
| 4.6.1. | Key Players in Human Therapeutics |
| 4.6.2. | Synthetic Biology in Human Therapeutics |
| 4.6.3. | Alternative Sources of Therapeutic Proteins |
| 4.6.4. | Changing the Microbiome as Therapy |
| 4.6.5. | Vedanta Biosciences |
| 4.6.6. | Gene and Cell Therapies |
| 4.6.7. | Spark Therapeutics |
| 4.6.8. | Chimeric Antigen Receptor T-Cell Therapy |
| 4.6.9. | CAR-T: Companies |
| 4.6.10. | Kite Pharma (Gilead Sciences) |
| 4.6.11. | The Outlook for Synthetic Biology in Human Therapeutics |
| 5. | REGULATION |
| 5.1. | Where Regulation is at Currently for Genetic Engineering |
| 5.2. | The Global Differences in Regulation for Genetic Engineering |
| 5.3. | Area of Genetically Engineered Crops by Country, 2016 |
| 5.4. | Regulation of Human Gene Editing Varies |
| 5.5. | Regulation of Gene and Cell Therapies |
| 5.6. | The Growing Concern of Biosecurity |
| 5.7. | Policing Synthetic Biology |
| 5.8. | Genetically Modified Organisms is NOT the Correct Term |
| 5.9. | Learning Lessons from the Past: Golden Rice |
| 5.10. | Impact on Economies, and Changing Opinions |
| 5.11. | To GM, or not to GM...That is the Question |
| 6. | INVESTMENT IN SYNTHETIC BIOLOGY |
| 6.1. | Synthetic Biology Funding Continues to Increase |
| 6.2. | Synthetic Biology Companies Attracted $1.7B Funding in 2017 |
| 6.3. | 2018 is Set to Be Another Record-Breaking Year |
| 6.4. | Turning Synthetic Biology into a Global Enterprise |
| 6.5. | Investment Forecast 2018 - 2023 |
| 7. | APPENDIX |
| 7.1. | Common Definitions & Acronyms in Synthetic Biology |
| 7.2. | List of Abbreviations |
| Slides | 178 |
|---|---|
| Forecasts to | 2023 |